全文获取类型
收费全文 | 13437篇 |
免费 | 1210篇 |
国内免费 | 324篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 195篇 |
妇产科学 | 335篇 |
基础医学 | 847篇 |
口腔科学 | 176篇 |
临床医学 | 1889篇 |
内科学 | 4983篇 |
皮肤病学 | 93篇 |
神经病学 | 473篇 |
特种医学 | 385篇 |
外科学 | 1306篇 |
综合类 | 1103篇 |
现状与发展 | 4篇 |
预防医学 | 1244篇 |
眼科学 | 37篇 |
药学 | 1462篇 |
6篇 | |
中国医学 | 322篇 |
肿瘤学 | 100篇 |
出版年
2024年 | 19篇 |
2023年 | 416篇 |
2022年 | 448篇 |
2021年 | 988篇 |
2020年 | 926篇 |
2019年 | 916篇 |
2018年 | 803篇 |
2017年 | 523篇 |
2016年 | 486篇 |
2015年 | 507篇 |
2014年 | 845篇 |
2013年 | 1370篇 |
2012年 | 573篇 |
2011年 | 706篇 |
2010年 | 531篇 |
2009年 | 490篇 |
2008年 | 541篇 |
2007年 | 528篇 |
2006年 | 441篇 |
2005年 | 367篇 |
2004年 | 342篇 |
2003年 | 288篇 |
2002年 | 241篇 |
2001年 | 229篇 |
2000年 | 171篇 |
1999年 | 146篇 |
1998年 | 108篇 |
1997年 | 119篇 |
1996年 | 95篇 |
1995年 | 75篇 |
1994年 | 72篇 |
1993年 | 67篇 |
1992年 | 85篇 |
1991年 | 70篇 |
1990年 | 43篇 |
1989年 | 46篇 |
1988年 | 50篇 |
1987年 | 35篇 |
1986年 | 39篇 |
1985年 | 53篇 |
1984年 | 37篇 |
1983年 | 29篇 |
1982年 | 25篇 |
1981年 | 7篇 |
1980年 | 18篇 |
1979年 | 14篇 |
1978年 | 12篇 |
1977年 | 15篇 |
1974年 | 4篇 |
1972年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
XI Hui CHENG Guan Liang HU Fei Fei LI Song Nan DENG Xuan ZHOU Yong 《Biomedical and environmental sciences : BES》2022,35(3):206-214
Objective To explore associations between lipoprotein-associated phospholipase A2(Lp-PLA2) and the risk of cardiovascular events in a Chinese population, with a long-term follow-up.Methods A random sample of 2,031 participants(73.6% males, mean age = 60.4 years) was derived from the Asymptomatic Polyvascular Abnormalities Community study(APAC) from 2010 to 2011. Serum Lp-PLA2 levels were determined by enzyme-linked immunosorbent assay(ELISA). The composite endpoint was a combination of first-eve... 相似文献
3.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(3):301-310
Background and objectiveTo describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of Spain.Material and methodsRetrospective, observational and multicentric study that included patients initiating treatment with evolocumab (from February 2016 to August 2018), in 15 Nephrology Units in Spain. The demographic and clinical characteristics of the patients, the lipid lowering treatment and the evolution of the lipid profiles between 24 weeks pre-initiation and 12 ± 4 weeks post-initiation of evolocumab were reviewed.ResultsSixty patients were enrolled: 53.3% women; mean (SD) age, 56.9 (12.8) years, 45.0% with familial hypercholesterolemia (FH) (5.0% homozygous and 40.0% heterozygous) and 65.0% with atherosclerotic cardiovascular (CV) disease. The mean (SD) eGFR was 62.6 (30.0) ml/min/1.73 m2 (51.7% of patients had eGFR < 60 ml/min/1.73 m2 [CKD stage > 2]), 50.0% had proteinuria (>300 mg/g) and 10.0% had nephrotic syndrome. Other CV risk factors were hypertension (75.0%), diabetes (25.0%), and smoking (21.7%). A 40.0% of patients were statin intolerant. At evolocumab initiation, 41.7% of patients were on a high-intensity statin, 18.3% on moderate intensity statin and 50.0% were receiving ezetimibe. Mean (SD) LDL-c at evolocumab initiation was 179.7 (62.9) mg/dL (53.4% of patients with LDL-c≥160 mg/dL and 29.3%≥190 mg/dL). After 12 weeks, evolocumab resulted in LDL-c reductions of 60.1%. At week 12, 90.0% of patients reached LDL-c levels <100 mg/dL, 70.0% <70 mg/dL, and 55.0% <55 mg/dL, while mean eGFR levels and statin use were remained stable.ConclusionIn Nephrology Units of Spain, evolocumab was predominantly prescribed in patients with FH, chronic renal disease (CRD>2) and secondary prevention, with LDL-c levels above those recommended by the guidelines. Evolocumab used in clinical practice significantly reduced the LDL-c levels in all patients included in the study. 相似文献
4.
5.
6.
7.
8.
9.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
10.
随着生活方式的改变,心脑血管疾病逐渐成为全人类死亡的“头号杀手”高于恶性肿瘤、糖尿病等。血脂的升高尤其是低密度脂蛋白胆固醇( LDL-C)的升高与动脉粥样硬化性心血管疾病( ASCVD)的发,生、发展息息相关。现有的专家共识、南提出他汀类药物是降低 LDL-C的一线用药,但仍可能会发生复发性缺血事件。人前蛋白转化酶枯草溶菌素 9(PCSK9)抑制指剂作为一类新型降脂药,有显著降低血 LDL-C水平,同时又可降低脂蛋白( a)的水平,又与 ASCVD与静脉血栓栓塞疾病( VTE)的发病可能相关。本文将系统地阐述新型降脂药 PCSK9抑制剂与 ASCVD、VTE的关系研究进展。 相似文献